LARSON MATTHEW PAUL
Known title: Chief Risk OfficerCIK: 0002114934
Associated companies
Transaction History
| SLDE | ▲ Buy | Option Exercise | 11,374 | $16K | 9/14/2026 | View on chart |
| SLDE | ▼ Sell | Open Market | 11,374 | $296K | 9/14/2026 | View on chart |
| SLDE | ▲ Buy | Option Exercise | 11,374 | $16K | 9/3/2026 | View on chart |
| SLDE | ▼ Sell | Open Market | 11,374 | $280K | 9/3/2026 | View on chart |
| SLDE | ▲ Buy | Option Exercise | 4,752 | $7K | 6/10/2026 | View on chart |
| SLDE | ▲ Buy | Option Exercise | 8,998 | $7K | 6/10/2026 | View on chart |
| SLDE | ▼ Sell | Open Market | 13,750 | $235K | 6/10/2026 | View on chart |
| SLDE | ▲ Buy | Option Exercise | 2,500 | $2K | 6/1/2026 | View on chart |
| SLDE | ▼ Sell | Open Market | 2,500 | $44K | 6/1/2026 | View on chart |
| SLDE | ▼ Sell | Open Market | 11,250 | $209K | 5/26/2026 | View on chart |
| SLDE | ▲ Buy | Option Exercise | 11,250 | $9K | 5/26/2026 | View on chart |
| SLDE | ▼ Sell | Open Market | 16,250 | $309K | 5/18/2026 | View on chart |
| SLDE | ▲ Buy | Option Exercise | 16,250 | $13K | 5/18/2026 | View on chart |
| SLDE | ▲ Buy | Option Exercise | 11,250 | $9K | 5/11/2026 | View on chart |
| SLDE | ▼ Sell | Open Market | 11,250 | $210K | 5/11/2026 | View on chart |
| SLDE | ▼ Sell | Open Market | 5,000 | $93K | 5/4/2026 | View on chart |
| SLDE | ▲ Buy | Option Exercise | 5,000 | $4K | 5/4/2026 | View on chart |
| SLDE | ▲ Buy | Option Exercise | 44,752 | $35K | 4/29/2026 | View on chart |
| SLDE | ▼ Sell | Open Market | 44,752 | $896K | 4/29/2026 | View on chart |
| SLDE | ▲ Buy | Option Exercise | 1,250 | $988 | 4/27/2026 | View on chart |
| SLDE | ▼ Sell | Open Market | 1,250 | $23K | 4/27/2026 | View on chart |
| SLDE | ▲ Buy | Option Exercise | 10,000 | $8K | 4/27/2026 | View on chart |
| SLDE | ▼ Sell | Open Market | 10,000 | $188K | 4/27/2026 | View on chart |
| SLDE | ▼ Sell | Open Market | 11,250 | $218K | 4/20/2026 | View on chart |
| SLDE | ▲ Buy | Option Exercise | 11,250 | $9K | 4/20/2026 | View on chart |
| SLDE | ▲ Buy | Option Exercise | 8,750 | $7K | 4/16/2026 | View on chart |
| SLDE | ▼ Sell | Open Market | 8,750 | $166K | 4/16/2026 | View on chart |
| SLDE | ▲ Buy | Option Exercise | 10,000 | $8K | 4/13/2026 | View on chart |
| SLDE | ▼ Sell | Open Market | 10,000 | $180K | 4/13/2026 | View on chart |
| SLDE | ▲ Buy | Option Exercise | 11,250 | $9K | 4/6/2026 | View on chart |
| SLDE | ▼ Sell | Open Market | 11,250 | $203K | 4/6/2026 | View on chart |
| SLDE | ▲ Buy | Option Exercise | 11,250 | $9K | 3/30/2026 | View on chart |
| SLDE | ▼ Sell | Open Market | 11,250 | $203K | 3/30/2026 | View on chart |
| SLDE | ▼ Sell | Open Market | 11,250 | $203K | 3/24/2026 | View on chart |
| SLDE | ▲ Buy | Option Exercise | 11,250 | $9K | 3/24/2026 | View on chart |
| SLDE | ▲ Buy | Option Exercise | 11,250 | $9K | 3/16/2026 | View on chart |
| SLDE | ▼ Sell | Open Market | 11,250 | $203K | 3/16/2026 | View on chart |
| SLDE | ▲ Buy | Option Exercise | 11,250 | $9K | 3/3/2026 | View on chart |
| SLDE | ▼ Sell | Open Market | 11,250 | $214K | 3/3/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Citizens Upgrades Slide Insurance, Raises Target to $28
Citizens Securities keeps its market outperform rating for Slide Insurance and lifted its price target to $28. A chart analysis from ChartMill notes the stock has entered the Minervini trend template and meets a high‑growth momentum screen. The shares trade near the upper end of their 52‑week range and sit above a key support level of $18.35. The company’s low trailing P/E of 4.7 suggests a valuation that may be attractive relative to the new target.
Citizens Upgrades Slide Insurance, Raises Target to $28. Citizens Securities keeps its market outperform rating for Slide Insurance and lifted its price target to $28. A chart analysis from ChartMill notes the stock has entered the Minervini trend template and meets a high‑growth momentum screen. The shares trade near the upper end of their 52‑week range and sit above a key support level of $18.35. The company’s low trailing P/E of 4.7 suggests a valuation that may be attractive relative to the new target.